A clinical retrospective analysis of the past five years of severe cyclosporine A-related neurotoxicity after allogeneic hematopoietic stem cell transplantation

徐雪丹,秦芳梅,周红升,江千里,张钰,范志平,马庆辉,刘启发,孙竞
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2014.10.010
2014-01-01
Abstract:Objective To investigate the incidence,clinical characteristics and the influencing factors of severe cyelosporine A (CsA)-related neurotoxicity (SNCT) in the patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the past five years.Method A retrospective analysis of 16 SNCT patients was carried out on 390 allo-HSCT recipients from June 2008 to June 2013.The clinical manifestations,imaging characteristics,treatment and outcome were observed.Result 4.1% (16/390) were identified to have SNCT,mainly for symptomatic epilepsy,including hypertension (n =6),electrolyte imbalance (n =12),elevated CsA concentration (n =12),and combined use of novel triazole drugs (n =13).MRI performed on 10 patients after SNCT showed that 7 patients was abnormal,including 4 cases of PRES.CSF examination in 6 patients showed that there patients had mild abnormalities.After withdrawal or extenuation of CsA,11 patients had complete recovery,two had partial recovery and three died of SNCT.SNCT-related mortality was 18.75% (3/16) and overall survival was 50% (8/16).Conclusion SNCT is not common,rapid progress and one of the most severe complications after allo-HSCT.MRI and electrolyte indicators can facilitate early diagnosis.It is recommended to closely monitor the concentration of CsA when combining CsA and novel triazole drugs.Raising awareness of early diagnosis of SNCT and taking active management of early transplant complications may help reduce the SNCT-related mortality.
What problem does this paper attempt to address?